Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
How to Switch from Semaglutide to Tirzepatide Step 1: Consult Your Healthcare Provider The first step in making the switch is to have an open conversation with your healthcare provider
Both medications can cause nausea as a common side effect
Red flag symptoms requiring urgent assessment: Severe, persistent vomiting Inability to tolerate oral intake for more than 24 hours, suggesting possible gastroparesis or other complications Signs of dehydration Decreased urine output, dizziness, dry mucous membranes, or tachycardia Severe abdominal pain Particularly if acute, localized, or associated with fever, which may indicate pancreatitis or other acute abdominal pathology Right upper quadrant pain, fever, or jaundice Suggesting possible gallbladder disease Severe abdominal distension with inability to pass stool or gas Potential bowel obstruction or ileus Hematemesis or melena Suggesting gastrointestinal bleeding Progressive dysphagia Difficulty swallowing that worsens over time Situations requiring routine consultation: Patients should contact their healthcare provider for non-urgent evaluation when experiencing persistent nausea or vomiting lasting beyond 2-3 weeks at a stable dose, as this may indicate inadequate adaptation or the need for dose adjustment
Observational reports have noted changes in alcohol consumption among some patients prescribed tirzepatide for diabetes or obesity
At 24 weeks, the 10 mg and 15 mg tirzepatide groups also spent more time in the target range compared to the insulin group
Phase 3 trials have now initiated for overweight and obesity at this point, assessing CagriSema in larger numbers and for longer periods of time. References: Frias JP, et al
US$ 22.77
US$ 20.95
US$ 21.24
US$ 27.61
US$ 27.73
